efgivanermin alfa

{
  "id": "MLC-T-ONC-013221",
  "term": "efgivanermin alfa",
  "field": "Oncology and biomedicine",
  "definition": "A homogenous hexameric agonist fusion protein composed of the extracellular domain (ECD) of the T-cell costimulatory receptor human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR) ligand (GITRL) and an immunoglobulin (Ig) G1 Fc domain, with potential immunomodulating and antineoplastic activities. Upon administration, efgivanermin alfa binds to and activates GITR found on multiple types of T cells, thereby inducing both the activation and proliferation of tumor antigen-specific T-effector cells. This abrogates the suppression of T-effector cells which is induced by inappropriately activated T-regulatory cells (Tregs), suppresses Tregs and decreases Treg tumor infiltration, and activates the immune system to help eradicate tumor cells. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including Tregs, effector T cells, B cells, dendritic cells (DCs) and natural killer (NK) cells.",
  "synonyms": [
    "TNFRSF18 agonist MEDI1873",
    "TNFRSF18 protein stimulant MEDI1873",
    "GITR stimulant MEDI1873",
    "GITR agonist MEDI1873"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/efgivanermin-alfa/"
}